AstraZeneca/Sanofi’s Nirsevimab Nears US FDA Approval After Overwhelmingly Positive Adcomm
Executive Summary
When patients should receive the RSV prevention treatment was the subject of much debate even as the Antimicrobial Drugs Advisory Committee voted nearly unanimously that it should be approved for infants and neonates.
You may also be interested in...
Supplemental Filings: FDA-CMS Collaboration, Beyfortus Approved For Pediatric RSV, Gavreto Loses An Indication, Sanders' Biosimilar Auto-Interchangeability Bill
CDER Director Cavazzoni has her description of CMS’ mandate corrected, the FDA approves AstraZeneca/Sanofi's nirsevimab but requires safety studies on RSV variants, Genentech and Blueprint Medicines withdraw Gavreto's medullary thyroid cancer claim due to confirmatory trial feasibility issues, and Bernie Sanders goes bold on biosimilars.
Cool Down: US FDA’s July User Fee Calendar Suggests Slower Pace After Torrid June
FDA action is expected on a handful of novel agents, including Daiichi Sankyo’s quizartinib, and conversion to full approval for Eisai/Biogen’s Leqembi.
‘Eye-Popping Cost Of Redundancy:’ Will US Market Find Place For RSV Prevention Meds And Vaccines?
A CDC work group seems to be leaning towards recommending choosing either Pfizer’s maternal vaccination for infant RSV or AstraZeneca/Sanofi’s preventative antibody treatment in babies but not both, in part due to the high costs. What happens to the already available Synagis antibody is another wildcard.